Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 105   

Articles published

ALKS 59.98 +1.48 (2.53%)
price chart
Alkermes Plc Price Target Increased to $79.00 by Analysts at Barclays (ALKS)
Alkermes Plc logo Alkermes Plc (NASDAQ:ALKS) had its price target boosted by equities researchers at Barclays from $77.00 to $79.00 in a research report issued to clients and investors on Wednesday, Market Beat.
Large Inflow of Money Witnessed in Alkermes plc  American Trade Journal
Alkermes Plc Rating Reiterated by Credit Suisse (ALKS)  Financial Wisdom Works
Alkermes Plc Ord (NASDAQ:ALKS): Alkermes Plc Ord to report earnings on ...
146.69M. This represents a 3.19% difference between analyst expectations and the Alkermes Plc Ord achieved in its quarterly earnings.
Credit Suisse Reaffirms "Buy" Rating for Alkermes Plc (ALKS)
Alkermes Plc (NASDAQ:ALKS)'s stock had its “buy” rating reissued by equities research analysts at Credit Suisse in a report released on Tuesday, Analyst Ratings Network.
Alkermes Plc. (ALKS) Discloses Form 4 Insider Selling : Exec. Robert A ...  American Trade Journal
Shares of Alkermes plc (NASDAQ:ALKS) Sees Large Inflow of Net Money  News Watch International
Alkermes plc (NASDAQ:ALKS) Expected to report EPS of $-0.28: Analysts
Alkermes plc (NASDAQ:ALKS) is expected to report earnings of $-0.28 per share for the current quarter. This is the Zacks Consensus number based on the sell-side analysts polled, which can slightly deviate from the Thomson Reuters' consensus typically ...
(ALKS) (ACE) (MMM) (NEE) Active News Update: Alkermes Plc (NASDAQ:ALKS), ACE ...
Alkermes plc (ALKS) declared that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Company Shares of Alkermes plc (NASDAQ:ALKS) Drops by -1.82%
Alkermes plc (NASDAQ:ALKS) has lost 1.82% during the past week and dropped 6.35% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.83%.
Alkermes up 6.5% on FDA approval of schizophrenia treatment
The drug, an extended-release injectable suspension, is the first atypical antipsychotic with monthly and six-week dosing options, to maintain therapeutic levels in the body.
Alkermes' schizophrenia drug Aristada gets FDA nod  Fox News
Long-lasting antipsychotic by Alkermes gets OK  The Boston Globe
Alkermes plc Short Interest Update
Alkermes plc (NASDAQ:ALKS), A drop of 656,011 shares or 7.6% was seen in the short interest of Alkermes plc - Ordinary Shares.
Insider Trading: Alkermes Plc (NASDAQ:ALKS)'s President - Alkermes plc ...
Alkermes Plc. (ALKS) Files Form 4 Insider Selling : Shane Cooke Sells 18000 ...  Insider Trading Report
Ratings and Sentiment Update on Alkermes plc (NASDAQ:ALKS)
Shares of Alkermes plc (NASDAQ:ALKS) have been given a Buy-Sell rating of 2.14 by Zacks Research. This is based on 6 analyst reports taken into consideration.
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ:ALKS) today announced that it has entered into a definitive agreement to sell its manufacturing facility in Gainesville, GA, the manufacturing and royalty revenue associated with products manufactured at ...
Recro Pharma (REPH) to Acquire Alkermes' (ALKS) Gainesville Facility in ...